Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith C Meyer

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
The Journal of Clinical Investigation|February 6, 2002
Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patientsDieter Worlitzsch, Robert Tarran, Martina Ulrich, et al.
American Journal of Respiratory and Critical Care Medicine|December 14, 2004
Quantitative and qualitative analysis of rhinovirus infection in bronchial tissuesAnne G Mosser, Rose Vrtis, Lacinda Burchell, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 30, 2010
Alveolar inflammation in cystic fibrosisMartina Ulrich, Dieter Worlitzsch, Simona Viglio, et al.
Chest|November 8, 2012
Executive summary: monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesRobert P Baughman, Keith C Meyer, Ian Nathanson, et al.
Chest|November 8, 2012
Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesRobert P Baughman, Keith C Meyer, Ian Nathanson, et al.
American Journal of Respiratory and Critical Care Medicine|May 3, 2012
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung diseaseKeith C Meyer, Ganesh Raghu, Robert P Baughman, et al.
Respiratory Research|May 21, 2022
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension studyGanesh Raghu, Mark J Hamblin, A Whitney Brown, et al.
American Journal of Respiratory Cell and Molecular Biology|October 19, 2013
Dysregulation of galectin-3. Implications for Hermansky-Pudlak syndrome pulmonary fibrosisAndrew R Cullinane, Caroline Yeager, Heidi Dorward, et al.
The Journal of Clinical Investigation|October 30, 2007
IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplantsWilliam J Burlingham, Robert B Love, Ewa Jankowska-Gan, et al.
JAMA|May 26, 2018
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical TrialGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
The Journal of Clinical Investigation|February 6, 2002
Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patientsDieter Worlitzsch, Robert Tarran, Martina Ulrich, et al.
American Journal of Respiratory and Critical Care Medicine|December 14, 2004
Quantitative and qualitative analysis of rhinovirus infection in bronchial tissuesAnne G Mosser, Rose Vrtis, Lacinda Burchell, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 30, 2010
Alveolar inflammation in cystic fibrosisMartina Ulrich, Dieter Worlitzsch, Simona Viglio, et al.
Chest|November 8, 2012
Executive summary: monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesRobert P Baughman, Keith C Meyer, Ian Nathanson, et al.
Chest|November 8, 2012
Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesRobert P Baughman, Keith C Meyer, Ian Nathanson, et al.
American Journal of Respiratory and Critical Care Medicine|May 3, 2012
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung diseaseKeith C Meyer, Ganesh Raghu, Robert P Baughman, et al.
Respiratory Research|May 21, 2022
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension studyGanesh Raghu, Mark J Hamblin, A Whitney Brown, et al.
American Journal of Respiratory Cell and Molecular Biology|October 19, 2013
Dysregulation of galectin-3. Implications for Hermansky-Pudlak syndrome pulmonary fibrosisAndrew R Cullinane, Caroline Yeager, Heidi Dorward, et al.
The Journal of Clinical Investigation|October 30, 2007
IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplantsWilliam J Burlingham, Robert B Love, Ewa Jankowska-Gan, et al.
JAMA|May 26, 2018
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical TrialGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.
Pageof 10